Retinoic ointment, 0.05% 15 g

Isotretinoin is one of the biologically active forms of vitamin A.

It inhibits terminal differentiation of sebocytes and hyperproliferation of epithelium of sebaceous glands outlet ducts, normalizes the composition of their secret and facilitates its evacuation.

Indications

For oral administration: severe cystic nodular acne, especially with localization on the trunk.

For rectal use: severe relapsing forms of acne, rashes with associated seborrheic process.

For external use: papulopustular acne, seborrhea, pink acne, perioral dermatitis.

Active ingredient

Composition

Interaction

The effect of isotretinoin is weakened by concomitant use of progesterone in microdoses.

The simultaneous use of isotretinoin and vitamin A may increase toxic effects.

The concomitant use of isotretinoin and aminoglycoside antibiotics carries a risk of intracranial hypertension.

Directions for use

The ointment is applied in a thin layer on the affected areas of the skin twice a day.

The duration of treatment is 4-12 weeks. The repeated course of treatment is possible after consultation with a doctor.

Special Instructions

Rectally and topically use with caution in liver diseases, kidney disease, chronic pancreatitis, decompensation of cardiac activity, chronic intoxications (including alcoholic).

In case of rectal and external application in case of acute exacerbation reaction (in the 1st-2nd week of treatment) it is recommended to cancel treatment for several days until its subsiding, after that the therapy can be resumed.

In case of oral administration it is necessary to regularly monitor liver function and plasma lipid levels before treatment, 1 month after the start of therapy, and then every 3 months.

In case of diabetes mellitus, obesity, alcoholism or lipid metabolism disorders, more frequent monitoring of laboratory parameters is recommended. If diabetes mellitus is present or suspected, plasma glucose levels should be strictly monitored.

Long-term use may cause symptoms of chronic hypervitaminosis A.

During treatment or for some time after its completion, women of childbearing age should not be donors.

Patients should not be given UV therapy during therapy, and patients should avoid direct exposure to sunlight.

In the course of treatment, contact lens intolerance may occur.

The safety in children and prepubertal patients has not been established.

The concomitant use of isotretinoin and 19-nortestosterone derivatives should be avoided, especially in patients with gynecological/endocrinological disorders.

The concomitant use of other drugs with keratolytic or exfoliative properties (including other retinoids) and progesterone in microdoses (including minipilli preparations) is not recommended.

Contraindications

Hypersensitivity, chronic liver disease, kidney disease, chronic pancreatitis, decompensation of cardiac activity.

Side effects

In the second week of treatment, there may be an exacerbation reaction – the appearance of new rashes, itching, swelling, redness and peeling of the skin.

In case of local reactions, it is recommended to stop treatment for a few days until it subsides. In some cases, in case of individual sensitivity, at the beginning of treatment, a patchy-papular rash, itching and swelling may occur.

In such cases the drug should be discontinued. With long-term use symptoms of chronic hypervitaminosis A (cheilitis, conjunctivitis, dry and peeling skin) may develop.

Pregnancy use

Similarities